SCHEMBL10128616

SCHEMBL10128616

CCCCCCCOc1ccc(-c2ccc(C)cc2)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARB P10826 3/20 0.63
NR5A1 Q13285 1/20 0.61
CYP3A4 P08684 3/20 0.59
CYP2D6 P10635 3/20 0.59
LTA4H P09960 3/20 0.55
CYP19A1 P11511 2/20 0.54
CYP2C9 P11712 2/20 0.54
CYP2C19 P33261 2/20 0.54
TP53 P04637 1/20 0.54
TSHR P16473 1/20 0.54
CYP1A2 P05177 1/20 0.54
PLA2G4B P0C869 1/20 0.53
DRD2 P14416 1/20 0.52
DRD4 P21917 1/20 0.52
DRD3 P35462 1/20 0.52
KDM4E B2RXH2 2/20 0.51
ALDH1A1 P00352 2/20 0.51
HPGD P15428 2/20 0.51
HTT P42858 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10128654 1.00 RARB (0.63) RARBNR5A1CYP3A4CYP2D6LTA4H
SCHEMBL24727755 1.00 RARB (0.63) RARBNR5A1CYP3A4CYP2D6LTA4H
SCHEMBL17951695 1.00 RARB (0.63) RARBNR5A1CYP3A4CYP2D6LTA4H
SCHEMBL8239315 1.00 RARB (0.63) RARBNR5A1CYP3A4CYP2D6LTA4H
SCHEMBL13402142 0.98 RARB (0.61) RARBNR5A1CYP3A4CYP2D6LTA4H
SCHEMBL12562032 0.98 CYP2D6 (0.61) RARBNR5A1CYP3A4CYP2D6LTA4H
SCHEMBL7733970 0.98 CYP2D6 (0.61) RARBNR5A1CYP3A4CYP2D6LTA4H
SCHEMBL21167283 0.94 NR5A1 (0.68) RARBNR5A1LTA4HTP53TSHR
SCHEMBL13991627 0.94 NR5A1 (0.68) RARBNR5A1LTA4HTP53TSHR
SCHEMBL22207172 0.94 NR5A1 (0.68) RARBNR5A1LTA4HTP53TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024137915-A1 BORON-CONTAINING CYCLIC EMISSIVE COMPOUNDS AND COLOR CONVERSION FILM CONTAINING THE SAME NITTO DENKO CORPORATION (US) 2024-06-27 WO disclosed
WO-2016201283-A1 ANTIFUNGAL AGENTS CIDARA THERAPEUTICS, INC. (US) 2016-12-15 WO disclosed
US-8119617-B2 aSMase inhibitors NOVARTIS AG (CH) 2012-02-21 US disclosed
US-8119617-B2 aSMase inhibitors NOVARTIS AG (CH) 2012-02-21 US disclosed
US-20100022482-A1 aSMase inhibitors NOVARTIS AG (CH) 2010-01-28 US disclosed
US-20100022482-A1 aSMase inhibitors NOVARTIS AG (CH) 2010-01-28 US disclosed
WO-2008022771-A1 AMIDES AS SPHINGOMYELINE INHIBITORS NOVARTIS AG (CH) 2008-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022482-A1 aSMase inhibitors SMPD1, SMPD3, SMPD2 RARB 4739/4885NR5A1 3322/4885CYP3A4 553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.